In a recent double-blind study, researchers determined cannabidiol (CBD) may be able to benefit patients who suffer from schizophrenia. In the study, researchers gave CBD to half of their enrolled volunteers, while they gave the other half placebo. Both groups used these medications in addition to their traditional therapies. Researchers found, "After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician… Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance and in overall functioning. CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups." The researchers also noted that, because CBD does not depend on dopamine receptor antagonism, the cannabinoid could become a new class of treatment of schizophrenia.
This information has be provided by Civilized and approved by our Chief Medical Officer.